| DIVISION OF NEPHROLOGY | |||
| Fund Source | Project Title | Start | End |
| Abul Ezz, Sameh | |||
| Satellite Healthcare (Co-I) | Meprin A and nidogen in acute kidney injury | 2007 | 2010 |
| Brosnahan, Godela | |||
| DaVita Clinical Research (PI) | Evaluation of Cinacalcet HCI therapy to lower cardiovascular events; Protocol No. 20050182-361 | 4/13/2007 | 5/31/2011 |
| Kaushal, Gur | |||
| Satellite Healthcare (PI) | Meprin A and Nidogen in acute kidney injury | 2007 | 2010 |
| UAMS Foundation Medical Research Endowment (PI) | Nidogen as a biomarker of early detection of acute kidney injury | 2008 | 2009 |
| Johnson & Johnson R&D (Janssen Pharma) | Role of Velcade in cisplatin nephrotoxicity | 2009 | 2010 |
| UAMS Pilot Study (PI) | Role of autophagy in acute kidney injury | 2008 | 2009 |
| Krause, Michelle | |||
| VA (PI) | Combination ace inhibitor/angiotensin receptor blocker for the treatment of diabetic nephropathy | 2008 | 2010 |
| Abbot (PI) | Chronic kidney disease (CKD) center of excellence program (chronic kidney disease education and screening for possible risk factors | 6/1/2005 | 5/31/2010 |
| FibroGen (PI) | FGCL-SM2216-019: A Randomized study of the safety and efficacy of FG-2216 in subjects with renal anemia not requiring dialysis and not receiving recombinant human erythropoietin | 11/13/2006 | 12/11/2008 |
| Mitsubishi Pharma & Kuraha Corps | A Phase III randomized, double-blind, placebo-controlled study of AS-120 for prevention of chronic kidney disease progression in patients w/ moderate to severe CKD | 2007 | 2011 |
| Davita-Clinical Research (PI) | A phase III, randomized, double-blind, placebo-controlled study of Tenecteplase for restoration of function in dysfunctional hemodialysis catheters | 2008 | 2009 |
| Megyesi, Judit | |||
| NIH / NIDDKD (Co-I) | Cyclin dependent kinase inhibitor in acute renal failure | 1998 | 2011 |
| VA (PI) | IPA - Judit Megyesi | 2007 | 2009 |
| VA Merit Review (Co-I) | The p21 cyclin-dependent kinase inhibitor in acute renal failure | 2005 | 2009 |
| Portilla, Didier | |||
| NIH / NIDDKD (PI) | Role of PPARalpha and L-FABP in acute renal failure | 6/1/2007 | 4/30/2011 |
| VA Merit (PI) |
Role of PPAR-alpha on glucose and fatty acid oxidation in acute renal failure. |
2004 | 12/2008 |
| Price, Peter | |||
| NIH / NIDDKD (PI) | Cyclin dependent kinase inhibitor in acute renal failure | 1998 | 2011 |
| VA Merit Review (PI) | The p21 cyclin-dependent kinase inhibitor in acute renal failure | 2005 | 2009 |
| Shah, Sudhir | |||
| NIH / NIDDKD (PI) | Training program in the pathophysiology of renal disease | 2006 | 2011 |
| NIH/NHLBI (Co-I) | LDL isoforms in kidney-related atherosclerosis | 2008 | 2010 |
| AHA (Co-I) | Role of chronic uremia and carbamylated LDL in atherosclerosis | 2008 | 2010 |
| NIH/NIDDKD (Co-I) | Premortem enzymatic DNA damage in kidney injury | 2008 | 2010 |
| VA Merit Review (PI) | Alternative splicing of endonucleases in kidney injury | 2007 | 2011 |
| Abbot (PI) | Chronic kidney disease (CKD) center of excellence program | 6/1/2005 | 5/31/2010 |
Contact regarding webpage content: GibAnn Berryhill
University of Arkansas for
Medical Sciences
College of Medicine
Department of Internal Medicine,
Slot 832
4301 W. Markham
Little Rock, AR 72205